Skip to main content
SpringerLink
Log in
Book cover

Small Molecules in Oncology

  • Book
  • © 2014

Overview

Editors:
  1. Uwe M. Martens

    1. Cancer Center Heilbronn-Franken, SLK-Kliniken Heilbronn GmbH Medizinische Klinik III, Heilbronn, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Detailed coverage of the most recent developments in targeted cancer therapy using small molecules
  • Full discussion of preclinical studies, clinical trials, and treatment applications
  • Written by acknowledged experts
  • Includes supplementary material: sn.pub/extras

Part of the book series: Recent Results in Cancer Research (RECENTCANCER, volume 201)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (25 chapters)

  1. Front Matter

    Pages i-xvi
    Download chapter PDF

  2. Imatinib Mesylate

    • Cornelius F. Waller
    Pages 1-25

  3. Dasatinib

    • Markus Lindauer, Andreas Hochhaus
    Pages 27-65

  4. Nilotinib

    • Benjamin N. Ostendorf, Philipp le Coutre, Theo D. Kim, Alfonso Quintás-Cardama
    Pages 67-80

  5. Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor

    • Susanne Isfort, Gunhild Keller-v. Amsberg, Philippe Schafhausen, Steffen Koschmieder, Tim H. Brümmendorf
    Pages 81-97

  6. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML

    • Julius Wehrle, Heike L. Pahl, Nikolas von Bubnoff
    Pages 99-107

  7. Erlotinib

    • M. Steins, M. Thomas, M. Geißler
    Pages 109-123

  8. Lapatinib

    • Minna Nolting, Tanja Schneider-Merck, Martin Trepel
    Pages 125-143

  9. Sorafenib: Targeting Multiple Tyrosine Kinases in Cancer

    • Jens Hasskarl
    Pages 145-164

  10. Sunitinib in the Treatment of Advanced Solid Tumors

    • Amal Imbulgoda, Daniel Y. C. Heng, Christian Kollmannsberger
    Pages 165-184

  11. Regorafenib

    • Thomas J. Ettrich, Thomas Seufferlein
    Pages 185-196

  12. Crizotinib

    • David F. Heigener, Martin Reck
    Pages 197-205

  13. Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor

    • Carsten Grüllich
    Pages 207-214

  14. Vemurafenib

    • Claus Garbe, Sail Abusaif, Thomas K. Eigentler
    Pages 215-225

  15. Dabrafenib

    • Radhika Kainthla, Kevin B. Kim, Gerald S. Falchook
    Pages 227-240

  16. Trametinib

    • Robert Zeiser
    Pages 241-248

  17. Ruxolitinib

    • Heiko Becker, Monika Engelhardt, Nikolas von Bubnoff, Ralph Wäsch
    Pages 249-257

  18. Ibrutinib

    • Mark-Alexander Schwarzbich, Matthias Witzens-Harig
    Pages 259-267

  19. Decitabine

    • Björn Hackanson, Michael Daskalakis
    Pages 269-297

  20. 5-Azacytidine/5-Azacitidine

    • Antonia M. S. Müller, Mareike Florek
    Pages 299-324
Back to top

Keywords

About this book

Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.

Reviews

“The book is recommended for healthcare professionals, scientists, and students in medical and scientific fields. In 25 well-written chapters, experts in their fields of research describe in great detail 12 compounds currently in clinical use for the treatment of hematological malignancies, and 13 compounds applicable to specific mutation-containing malignancies or aimed at interfering with the microenvironment (such as angiogenesis). … This book provides important practical information on a wide variety of novel small molecule-based treatment approaches.” (George Somlo, Doody's Book Reviews, April, 2015)

Editors and Affiliations

  • Cancer Center Heilbronn-Franken, SLK-Kliniken Heilbronn GmbH Medizinische Klinik III, Heilbronn, Germany

    Uwe M. Martens

Bibliographic Information

  • Book Title: Small Molecules in Oncology

  • Editors: Uwe M. Martens

  • Series Title: Recent Results in Cancer Research

  • DOI: https://doi.org/10.1007/978-3-642-54490-3

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer-Verlag Berlin Heidelberg 2014

  • Hardcover ISBN: 978-3-642-54489-7Published: 12 May 2014

  • Softcover ISBN: 978-3-662-51925-7Published: 23 August 2016

  • eBook ISBN: 978-3-642-54490-3Published: 22 April 2014

  • Series ISSN: 0080-0015

  • Series E-ISSN: 2197-6767

  • Edition Number: 2

  • Number of Pages: XVI, 417

  • Number of Illustrations: 20 b/w illustrations, 26 illustrations in colour

  • Additional Information: The third edition of this book will be published in two volumes

  • Topics: Oncology, Hematology, Cancer Research

Publish with us

Policies and ethics

Back to top

Search

Navigation